NEW YORK, Nov. 27, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning,
Market Source Research released its latest key findings for all current investors, traders, and shareholders of Martin Midstream
Partners L.P. (NASDAQ:MMLP), Galectin Therapeutics Inc. (NASDAQ:GALT), Mountain Province Diamonds Inc. (NASDAQ:MPVD), MINDBODY,
Inc. (NASDAQ:MB), Pareteum Corp. (NASDAQ:TEUM), and Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), including updated fundamental
summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
MMLP DOWNLOAD: http://MarketSourceResearch.com/register/?so=MMLP
GALT DOWNLOAD: http://MarketSourceResearch.com/register/?so=GALT
MPVD DOWNLOAD: http://MarketSourceResearch.com/register/?so=MPVD
MB DOWNLOAD: http://MarketSourceResearch.com/register/?so=MB
TEUM DOWNLOAD: http://MarketSourceResearch.com/register/?so=TEUM
PIRS DOWNLOAD: http://MarketSourceResearch.com/register/?so=PIRS
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Market Source Research, available for free download at the links above, examine
Martin Midstream Partners L.P. (NASDAQ:MMLP), Galectin Therapeutics Inc. (NASDAQ:GALT), Mountain Province Diamonds Inc.
(NASDAQ:MPVD), MINDBODY, Inc. (NASDAQ:MB), Pareteum Corp. (NASDAQ:TEUM), and Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) on a
fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business
strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are
available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone
summaries and as such, important information may be missing from these samples. Please download the entire research report, free of
charge, to ensure you are reading all relevant material information. All information in this release was accessed November 23rd,
2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
MARTIN MIDSTREAM PARTNERS L.P. (MMLP) REPORT OVERVIEW
Martin Midstream Partners' Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Martin Midstream Partners reported
revenue of $219.05MM vs $193.13MM (up 13.42%) and analysts estimated basic earnings per share $1.00 vs -$0.42. For the twelve
months ended December 31st, 2017 vs December 31st, 2016, Martin Midstream Partners reported revenue of $946.12MM vs $827.39MM (up
14.35%) and analysts estimated basic earnings per share $0.44 vs $0.65 (down 32.31%). Analysts expect earnings to be released on
February 13th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter
last year was $0.48. The estimated EPS forecast for the next fiscal year is $0.73 and is expected to report on February 13th,
2019.
To read the full Martin Midstream Partners L.P. (MMLP) report, download it here: http://MarketSourceResearch.com/register/?so=MMLP
-----------------------------------------
GALECTIN THERAPEUTICS INC. (GALT) REPORT OVERVIEW
Galectin Therapeutics' Recent Financial Performance
Analysts expect earnings to be released on April 4th, 2019. The report will be for the fiscal period ending
December 31st, 2018. Reported EPS for the same quarter last year was -$0.07. The estimated EPS forecast for the next fiscal year is
-$1.12 and is expected to report on April 4th, 2019.
To read the full Galectin Therapeutics Inc. (GALT) report, download it here: http://MarketSourceResearch.com/register/?so=GALT
-----------------------------------------
MOUNTAIN PROVINCE DIAMONDS INC. (MPVD) REPORT OVERVIEW
Mountain Province Diamonds' Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Mountain Province Diamonds reported
revenue of $57.29MM vs $52.04MM (up 10.10%) and analysts estimated basic earnings per share $0.06 vs $0.14 (down 55.00%). Analysts
expect earnings to be released on March 25th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported
EPS for the same quarter last year was -$0.08.
To read the full Mountain Province Diamonds Inc. (MPVD) report, download it here: http://MarketSourceResearch.com/register/?so=MPVD
-----------------------------------------
MINDBODY, INC. (MB) REPORT OVERVIEW
MINDBODY's Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, MINDBODY reported revenue of $63.78MM
vs $46.61MM (up 36.84%) and basic earnings per share -$0.36 vs -$0.08. For the twelve months ended December 31st, 2017 vs December
31st, 2016, MINDBODY reported revenue of $182.63MM vs $139.02MM (up 31.37%) and analysts estimated basic earnings per share -$0.33
vs -$0.58. Analysts expect earnings to be released on February 20th, 2019. The report will be for the fiscal period ending December
31st, 2018. The reported EPS for the same quarter last year was -$0.06. The estimated EPS forecast for the next fiscal year is
-$0.61 and is expected to report on February 20th, 2019.
To read the full MINDBODY, Inc. (MB) report, download it here: http://MarketSourceResearch.com/register/?so=MB
-----------------------------------------
PARETEUM CORP. (TEUM) REPORT OVERVIEW
Pareteum's Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Pareteum reported revenue of $8.01MM vs
$3.50MM (up 128.88%) and analysts estimated basic earnings per share -$0.12 vs -$0.16. For the twelve months ended December 31st,
2017 vs December 31st, 2016, Pareteum reported revenue of $13.55MM vs $12.86MM (up 5.38%) and analysts estimated basic earnings per
share -$0.84 vs -$4.56. Analysts expect earnings to be released on March 26th, 2019. The report will be for the fiscal period
ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.31. The estimated EPS forecast for the next
fiscal year is $0.14 and is expected to report on March 26th, 2019.
To read the full Pareteum Corp. (TEUM) report, download it here: http://MarketSourceResearch.com/register/?so=TEUM
-----------------------------------------
PIERIS PHARMACEUTICALS, INC. (PIRS) REPORT OVERVIEW
Pieris Pharmaceuticals' Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Pieris Pharmaceuticals reported revenue
of $8.35MM vs $3.93MM (up 112.50%) and analysts estimated basic earnings per share -$0.11 vs -$0.16. For the twelve months ended
December 31st, 2017 vs December 31st, 2016, Pieris Pharmaceuticals reported revenue of $25.28MM vs $5.83MM (up 333.46%) and
analysts estimated basic earnings per share -$0.40 vs -$0.55. Analysts expect earnings to be released on March 8th, 2019. The
report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.17. The
estimated EPS forecast for the next fiscal year is -$0.82 and is expected to report on March 8th, 2019.
To read the full Pieris Pharmaceuticals, Inc. (PIRS) report, download it here: http://MarketSourceResearch.com/register/?so=PIRS
-----------------------------------------
ABOUT MARKET SOURCE RESEARCH
Market Source Research delivers the key research reports that helps serious investors, registered brokers,
professional traders, and personal investment advisers find reliable information in today's markets. Market Source Research's team
is comprised of financial professionals, many of which hold Chartered Financial Analyst® (CFA®) designations and FINRA®
BrokerCheck® certifications. Whether identifying emerging trends, or discovering new opportunity, the team at Market Source
Research is dedicated to providing accurate, informative, and objective content that's ahead of the curve. With insights on
individual companies as well as sectors, readers get the industry's best available combination of big-picture perspective as well
as granular detail.
REGISTERED MEMBER STATUS
Market Source Research's oversight and audit staff are registered analysts, brokers, and/or financial advisers
("Registered Members") working within Equity Research, Media, and Compliance departments. Market Source Research's roster includes
qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers.
Current licensed status of several Registered Members at Market Source Research have been independently verified by an outside
audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries
regarding this release should be directed to Market Source Research's Compliance department by Phone, at +1 (704) 343-6361, or by
E-mail at compliance@MarketSourceResearch.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Market Source
Research, Market Source Research members, and/or Market Source Research affiliates are not responsible for any gains or losses that
result from the opinions expressed. Market Source Research makes no representations as to the completeness, accuracy, or timeliness
of the material provided and all materials are subject to change without notice. Market Source Research has not been compensated
for the publication of this press release by any of the above mentioned companies. Market Source Research is not a financial
advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration.
For our full disclaimer, disclosure, and terms of service please visit our website.
Media Contact:
Hugo Moreau, Media Department
Office: +1 (704) 343-6361
E-mail: media@MarketSourceResearch.com
© 2018 Market Source Research. All Rights Reserved. For republishing permissions, please contact a partner network
manager at partnership@MarketSourceResearch.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority,
Inc.
